Status:
COMPLETED
A Retro-/Prospective, Non-interventional, Cohort Study in Adult Patients With Locally Advanced or Metastatic Tumors With a Neurotrophic Tyrosine Receptor Kinase (NTRK) Gene Fusion, Treated With Larotrectinib
Lead Sponsor:
Centre Leon Berard
Collaborating Sponsors:
Bayer
Conditions:
Solid Tumor, Adult
Locally Advanced Solid Tumor
Eligibility:
All Genders
25+ years
Brief Summary
Larotrectinib, a selective TRK inhibitor has showed marked and durable antitumor activity in patients with NTRK gene-fusion-positive tumors regardless of the tumor type, gene partner and patient's age...
Detailed Description
Tropomyosin receptor kinases (TRK) are a family of tyrosine kinases that bind neurotrophins, a family of growth factors important to the formation and function of the nervous system. In cancer, the ne...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Adult male or female patients
- Histological confirmed diagnosis of advanced/metastatic solid tumor type.
- Patients previously, currently or to be treated with Larotrectinib within the ATU/post-ATU period. Patient must be \> 25 years-old at time of larotrectinib start.
- Patients not opposed to collection of personal clinical data
Exclusion
Key Trial Info
Start Date :
February 23 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
September 15 2024
Estimated Enrollment :
26 Patients enrolled
Trial Details
Trial ID
NCT04814667
Start Date
February 23 2021
End Date
September 15 2024
Last Update
December 20 2024
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU Amiens
Amiens, France
2
Centre Georges Francois Leclerc
Dijon, France
3
Centre Leon Berard
Lyon, France
4
Chi Elbeuf Louviers
Saint-Aubin-lès-Elbeuf, France